KR20230165285A - Gdf15 신호전달의 치료적 억제제 - Google Patents

Gdf15 신호전달의 치료적 억제제 Download PDF

Info

Publication number
KR20230165285A
KR20230165285A KR1020237037287A KR20237037287A KR20230165285A KR 20230165285 A KR20230165285 A KR 20230165285A KR 1020237037287 A KR1020237037287 A KR 1020237037287A KR 20237037287 A KR20237037287 A KR 20237037287A KR 20230165285 A KR20230165285 A KR 20230165285A
Authority
KR
South Korea
Prior art keywords
seq
domain
quel
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237037287A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 오라힐리
앤서니 패트릭 콜
아이린 시미노
에-치앙 리
후이 리우
아담 카펜터
Original Assignee
캠브리지 엔터프라이즈 리미티드
키맵 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed by 캠브리지 엔터프라이즈 리미티드, 키맵 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Publication of KR20230165285A publication Critical patent/KR20230165285A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237037287A 2021-03-31 2022-03-31 Gdf15 신호전달의 치료적 억제제 Pending KR20230165285A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2104556.2 2021-03-31
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GB2107331.7 2021-05-21
GB2108170.8 2021-06-08
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (1)

Publication Number Publication Date
KR20230165285A true KR20230165285A (ko) 2023-12-05

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037287A Pending KR20230165285A (ko) 2021-03-31 2022-03-31 Gdf15 신호전달의 치료적 억제제

Country Status (11)

Country Link
US (1) US20240182585A1 (https=)
EP (1) EP4314071A1 (https=)
JP (1) JP2024511853A (https=)
KR (1) KR20230165285A (https=)
AU (1) AU2022251923A1 (https=)
BR (1) BR112023020152A2 (https=)
CA (1) CA3215737A1 (https=)
CO (1) CO2023013791A2 (https=)
IL (1) IL307382A (https=)
MX (1) MX2023011655A (https=)
WO (1) WO2022207846A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
EP2441466B1 (en) 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
RS59045B1 (sr) 2012-09-26 2019-08-30 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
RS59700B1 (sr) 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
CN108463246B (zh) 2015-10-02 2025-02-28 尤利乌斯·马克西米利安维尔茨堡大学 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
US20170299608A1 (en) 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof

Also Published As

Publication number Publication date
US20240182585A1 (en) 2024-06-06
CA3215737A1 (en) 2022-10-06
JP2024511853A (ja) 2024-03-15
EP4314071A1 (en) 2024-02-07
AU2022251923A1 (en) 2023-11-16
WO2022207846A1 (en) 2022-10-06
MX2023011655A (es) 2023-10-11
IL307382A (en) 2023-11-01
CO2023013791A2 (es) 2024-01-25
BR112023020152A2 (pt) 2023-11-14

Similar Documents

Publication Publication Date Title
AU2022204078B2 (en) Combination therapies targeting PD-1, TIM-3, and LAG-3
KR102473028B1 (ko) 항-tim-3 항체 및 조성물
RU2755503C2 (ru) Анти-lag-3 антитела и их композиции
CN109689688B (zh) 抗icos抗体
US20090324602A1 (en) Anti-fn14 antibodies and uses thereof
TW200911833A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
PT2711375T (pt) Proteínas humanas de ligação a antigénios que se ligam a beta-klotho, recetores fgf e os seus complexos
TW201125581A (en) Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
KR20170105558A (ko) 항 alk2 항체
KR20230113295A (ko) Sars-cov-2에 대한 항체 및 그의 용도
CN115380049B (zh) 对生理性铁过载的治疗
KR20210068065A (ko) 안타고니스트
KR20230165285A (ko) Gdf15 신호전달의 치료적 억제제
DK2373335T3 (en) Monoclonal anti-ferroportin 1 antibodies and uses thereof
KR20220131293A (ko) 항-e-셀렉틴 항체, 조성물 및 사용 방법
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
KR20240019295A (ko) 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
CN117916262A (zh) Gdf15信号传导的治疗性抑制剂
RU2839429C2 (ru) Антагонисты
KR20240007760A (ko) 항-icos 항체의 용도
RU2795232C2 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
HK40082642A (en) Combination therapies targeting pd-1, tim-3, and lag-3
KR20210105396A (ko) 안타고니스트
HK40082642B (zh) 靶向pd-1、tim-3及lag-3的组合疗法
HK40003736B (en) Anti-icos antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250204

Comment text: Request for Examination of Application